Article

Hereditary Dementia Evident in Neuroimaging Early

Results from the Genetic Frontotemporal Dementia Initiative


 

References

In adults at risk of frontotemporal dementia, structural imaging and cognitive changes can be identified 5 to 10 years before the expected onset of symptoms, according to a multicenter neuroimaging study of subjects with and without genetic mutations associated with dementia.

The study population included 118 patients with a pathogenic mutation in one of three genes (GRN, MAPT, or C9orf72), of whom 40 were symptomatic and 78 were asymptomatic, and 102 non-carriers.

Imaging differences between carriers and non-carriers were first evident 10-years prior to expected onset of dementia, with reductions in the insula and temporal lobe.

Neuropsychological differences were first evident 5 years prior to expected onset, with significant differences in all measures but immediate recall and verbal fluency.

Citation: Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal Dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14(3):253-262. doi: 10.1016/S1474-4422(14)70324-2.

Recommended Reading

Conference News Update—Radiological Society of North America 2015
MDedge Neurology
Conference News Update—Society for Neuroscience 2014
MDedge Neurology
Pathologic proteins in Alzheimer’s, Parkinson’s also collect in skin cells
MDedge Neurology
Amyloid Imaging May Help Detect High Risk for Conversion From MCI to Alzheimer’s Disease
MDedge Neurology
How Does Depression Affect the Course of Neurologic Disease?
MDedge Neurology
Gout may lower Alzheimer’s risk
MDedge Neurology
Consortium opens Alzheimer’s data to global research community
MDedge Neurology
GAO calls for expanded efforts to reduce antipsychotic use in older dementia patients
MDedge Neurology
Study identifies factors for minimizing the impact of Alzheimer’s genetic risk
MDedge Neurology
Autopsy studies verify flutemetamol’s ability to identify brain beta-amyloid
MDedge Neurology